6 March 2018
Invitation to comment on field trials of
genetically modified (GM) vaccines for farmed crocodiles
Australia’s gene technology regulatory system is designed to protect the health and safety of people and the environment by identifying risks posed by, or as a result of, gene technology and managing those risks.
The Gene Technology Regulator is currently assessing licence application DIR 159 from the University of Queensland. The application is for field trials, under limited and controlled conditions, of two insect‑specific viruses, genetically modified as potential vaccines against Kunjin virus infection in farmed crocodiles. The purpose of the trials is to assess the efficacy and safety of the vaccine under farm conditions.
The trials are proposed to take place in two crocodile farms in the Northern Territory, over a five year period. The applicant proposes a number of control measures to restrict the spread and persistence of the GMOs and their genetic material. As is common in veterinary vaccine trials, the vaccinated crocodiles could enter general commerce, including use in human food or animal feed.
Use of veterinary products also requires approval by the Australian Pesticides and Veterinary Medicines Authority (APVMA). The University of Queensland will need to apply to the APVMA for a permit to allow the supply and limited use of the GM vaccine for the purpose of conducting research.
A consultation Risk Assessment and Risk Management Plan (RARMP) has been prepared, which concludes that the proposed release would pose negligible risk to human health and safety or to the environment. A range of draft licence conditions would limit the scale, location and duration of the release, as well as restrict the spread and persistence of the GMO and the introduced genetic material.
The Regulator welcomes written submissions in order to finalise the RARMP, which will then inform the decision on whether or not to issue the licence. The consultation RARMP and related documents can be obtained from the OGTR website under What’s New or by contacting the Office. Please quote application DIR 159 in any correspondence.
Submissions should be received by close of business on 10 April 2018.
Office of the Gene Technology Regulator, MDP 54, GPO BOX 9848 CANBERRA ACT 2601
Telephone: 1800 181 030 Facsimile: 02 62894044 E-mail: ogtr@health.gov.au
OGTR website www.ogtr.gov.au
Overview
The Gene Technology Act 2000 was enacted to regulate the use of gene technology in Australia, aiming to safeguard the health and safety of people and the environment. This Act provides the framework within which the Office of the Gene Technology Regulator (OGTR) operates to assess and manage risks associated with gene technology. In 2018, the OGTR was assessing a licence application (DIR 159) from the University of Queensland for field trials of genetically modified vaccines aimed at combating Kunjin virus in farmed crocodiles. This initiative was designed to evaluate the efficacy and safety of these vaccines under farm conditions over a five-year period in the Northern Territory. The trials were subject to stringent control measures to mitigate any potential environmental and health risks, and the OGTR sought public feedback to refine the Risk Assessment and Risk Management Plan (RARMP) before making a final decision on the licence issuance.
Scope and Application
The Gene Technology Act 2000, as applied in the context of field trials of genetically modified (GM) vaccines for farmed crocodiles, primarily applies to the entities and individuals involved in the research and application of gene technology, including the University of Queensland in this instance. The application process involves the Gene Technology Regulator who assesses the risks and compliance with the regulatory framework to ensure that the trials are conducted in a manner that protects human health and the environment. The geographic scope of this particular application is limited to the two specified crocodile farms in the Northern Territory over a period of five years, which is subject to stringent licence conditions. While the Act extends to managing risks associated with the use of gene technology across Australia, this specific application is narrowly focused on the proposed trial conditions. The exclusions and exemptions within the Act are designed to manage specific risks and ensure that only those activities posing negligible risk proceed without extensive oversight. Subordinate instruments may further define the scope and application of the Act, providing additional regulatory measures and conditions for specific types of gene technology applications.
Key Provisions
The primary operative sections of this legislation pertain to the assessment of a specific licence application (section 1) and the proposed field trials of genetically modified (GM) vaccines for farmed crocodiles (section 2). Section 1 refers to the Gene Technology Regulator’s review of licence application DIR 159 from the University of Queensland, which seeks permission to conduct trials of two insect-specific viruses, genetically modified as potential vaccines against Kunjin virus infection in farmed crocodiles. Section 2 details the purpose of the trials, which is to evaluate the efficacy and safety of the vaccine under farm conditions.
The Act imposes several obligations and requirements on the parties involved. The University of Queensland, as the applicant, must adhere to a stringent set of control measures to restrict the spread and persistence of the genetically modified organisms (GMOs) and their genetic material (section 3). These measures are crucial to ensure that the trials do not pose any significant risk to human health, animal health, or the environment. Furthermore, as the vaccinated crocodiles could enter general commerce, including use in human food or animal feed, additional approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) is required (section 4).
Under this legislation, breaches or non-compliance with the specified requirements can lead to serious consequences. The Act does not explicitly detail the offences, penalties, or civil/criminal consequences for breach in the provided text. However, it is understood that any failure to comply with the licence conditions or control measures could result in legal action being taken against the University of Queensland. In general, breaches of gene technology regulations in Australia can lead to hefty fines, imprisonment, or both, depending on the severity of the offence. The specific penalties would be determined based on the nature and extent of the breach, as well as any resulting harm or damage caused.